Ekf Diagnostics Share Discussion Threads

[cisk] 14/5/2021 15:38

Is Trellis the same as Verici, where even though the stock shows in your account you can't trade until quite some months after the ipo?

[cambridgedon] 14/5/2021 15:05

Thanks.
CD

[jacks13] 14/5/2021 14:28

It's my understanding that we are currently in a lock-up while we await the IPO, the transfer of the shares into holders' accounts and the AIM listing. Shareholders will be able to sell on the day of admission (28 May) as I understand it, in theory at least. Though this might not be the case for many as accounts may not be updated in time to permit trading on the first day of admission.

[cambridgedon] 14/5/2021 13:38

Please can someone remind me of the lock up conditions applicable to Trellus Health?
Also, when can we expect to see the shares in our trading accounts now the AIM admission date is announced as 28th May.
Thanks,
CD

[jacks13] 14/5/2021 12:06

Trellus was in the price* up until the distribution of EKF's shareholding. Or more precisely, until the in-specie distribution went ex-dividend back in December.

' ...In December, the Company transferred this shareholding to its then shareholders by way of a dividend in specie. It is expected that Trellus will complete an IPO in 2021.'

rns 30 March

*Whether or not Trellus was 'for free' is semantics. Maybe no value had been recognised in previous EKF accounts.

[shanklin] 14/5/2021 11:50

wan... I did listen to the interview... ...or rather the Chris Mills monologue.

My apologies for missing the comment re Trellus.

[wan] 14/5/2021 11:42

Shanklin...Not according to Chris Mills (if you listened to the interview) where he said "Trellus was in the price for free"

Rivaldo...Thanks for the heads-up.

[shanklin] 14/5/2021 11:17

wan

So the 64p/share included Trellus Health?

[tongosti] 14/5/2021 11:11

Share price failing to oblige gents - Mr Market has a logic different to "house" brokers. A close below 58 and (if it happens of course) and and we will be on a sailing trip South of Atlantic.

[rivaldo] 14/5/2021 10:49

RNS just out confirming Trellus Health to float on AIM on 28th May, with N+1 Singer as broker and Nomad:



"On 20 August 2020, EKF Diagnostics Holdings plc (EKF) announced that it had led, in partnership with ISMMS, a $5 million strategic investment into the Company. On 18 December 2020, EKF distributed its investment in the Company to EKF shareholders on its register at that time, by way of a dividend in specie of its entire holding of 27,999,999 non-voting Trellus A Shares. Transfer of these shares took place on 18 December 2020 to Broadway Nominees Limited to be held on trust for the underlying EKF shareholders. On Admission, all A Shares will convert to Ordinary Shares."

[wan] 14/5/2021 09:49

Edit - Interview link added to above post.

[wan] 14/5/2021 09:42

I decided I would remind myself what Chris Mills said in an interview on the 17th November 2020 regarding EKF when the share price was 64p. In short, there were a number of elements he regarded as being in the price for free at 64p, albeit he did state at some point they would have to sell some shares, as EKF would be too big a percentage of their portfolio, "but it sure ain't at this price" (64p). He also said EKF had "life way beyond COVID".

Interview (EKF at 15mins 40 seconds in)


So, as discussed on here, we probably know why Chris Mills sold some at 80p, but given his remarks regarding the price at 64p, investors will no doubt be wondering where the floor is. So, it will thus be interesting to see if we are there yet, but it is perhaps worth recalling that the directors are incentivised in the event that the Company is acquired by a third party. However, clearly Chris Mills expects more that 64p for their EKF shares, believing there are elements included in the price for free and plenty of growth to go for too beyond COVID, which apparently we will be updated on.

An exit is not something I would normally highlight, nor indeed promote ("not at this price"), but there is currently a lot of M&A in our sector. To be clear, an exit is currently not what I am wishing for though, but I do wonder whether some form of change is afoot.

Currently, I see more reasons to buy than sell, but investors should of course make up their own minds when making investment decisions etc.

[tongosti] 14/5/2021 09:11

This is a fan club as you may have noticed. Wait for someone to come back to you here telling you that nothing has changed / price moves are just nonsense etc etc. Seriously - an attempt to fail off previous highs raises serious questions. Folks forget we make money if and only if the market agrees with us. It happens far less frequently than most o would have one believe.

[wanttowin] 14/5/2021 08:23

Directors selling, price collapsing, what's going on here ??

[wan] 13/5/2021 09:11

I should have perhaps added to the above that the EKF/Longhorn sample collection media/devices are not specifically limited to collecting, inactivating/preserving COVID-19, and are applicable to other (new and existing) highly infectious diseases. A long a shelf life independent of refrigeration (up to 2 years), is another attribute (which also happens to dovetail rather well with home testing kits).

Thus, having the the ability to respond to new and existing virus outbreaks via rapid access to substantial sample collection stocks, and indeed having the appropriate manufacturing capacity, will also be strategically important factors in meeting future preparedness.

[wan] 13/5/2021 07:52

All eyes appears to be on the volume of COVID-19 testing (and inflation), but most of us appreciate EKF is about more than COVID testing, and if the Times journalist is correct, it would appear EKF will be updating us soon in this regard.

The virus is still circulating, albeit vaccines are thankfully having an effect. But the threat from variants appears very real, which can only be identified and observed by testing and will require the continued deployment of surge testing.

As an aside to the above and food for thought, through the NHS, recently I had to take a COVID pcr test and isolate for three days prior to a small procedure, will this be the new normal?

Whilst all eyes are fixated on testing volumes, I have not seen much about preparedness. The following recent articles though, caught my attention -

Global health system ‘unfit’ for purpose and major reform needed, concludes independent review

By
Paul Nuki,
GLOBAL HEALTH SECURITY EDITOR, LONDON and
Sarah Newey,
GLOBAL HEALTH SECURITY CORRESPONDENT
12 May 2021 • 11:00am

In the presentation of the report and its findings to the press, former President Sirleaf stressed the need for bold reform.

“Our message is simple and clear: the current system failed to protect us from the Covid-19 pandemic. And if we do not act to change it now, it will not protect us from the next pandemic threat, which could happen at any time.”

The report added that the world was repeatedly warned about the potential threat of a pandemic ahead of the Covid-19 outbreak but had failed to act.

Greater investment is also seen as crucial, now and in the future.

The report calls on the G7, currently led by the UK and set to meet in Cornwall next month, to “immediately commit” to provide 60 per cent of the US$19 billion required in 2021 for vaccines, diagnostics and therapeutics to fight Covid-19.

In the longer term, the report calls for the creation of an International Pandemic Financing Facility, which would have the capacity to mobilize long term (10-15 year) contributions of approximately US$5-10 billion a year to finance ongoing readiness globally.

The idea is to build a global contingency fund so US$50-100 billion could be disbursed at short notice in the event of a new outbreak.

The Global Health Threats Council would allocate and monitor the funding to institutions which have the capacity to support the development of preparedness and response capacities.

“Heads of state and government should at a global summit adopt a political declaration under the auspices of the UN General Assembly to commit to these transformative reforms”, it adds.

Full story -

Press Release
New York, NY (May 06, 2021)
Biopreparedness Expert Gustavo Palacios, PhD, to Join Mount Sinai, Strengthening Research Collaborations with Department of Defense

“I am delighted to welcome Dr. Palacios to our team as we continue to lead a national effort to understand new and emerging viruses and thwart future pandemics,” said Dr. Palese. “The globe has felt the devastation of the recent pandemics, which highlight the need to invest in research and development to end the current crisis and the next one in waiting. Public, private, government, and academic efforts are crucial to create a biopreparedness system for the country and the globe. We are excited to further strengthen our ties with government researchers and scientists who share a common goal of protecting public health.”

Mount Sinai Health System is uniquely positioned to become a biosurveillance network to detect emerging pathogens and evaluate medical countermeasures and diagnostic devices to allow rapid response. During outbreaks of emerging infectious diseases, the ability to collect specimens is crucial. Clinical samples are needed to determine baseline levels of host and pathogen biomarkers, as well as for determining clinical sensitivity and specificity values to inform diagnostic test development and refinement. The outbreak of SARS-CoV-2, the virus that causes COVID-19, during 2020 and West Nile virus in 1999 demonstrate the huge impact of travel and movement of goods in the introduction of emerging pathogens through New York City. The unique collaboration between Mount Sinai, the U.S. Army, and DoD is paramount to prepare for future events.

“To efficiently and effectively counter an epidemic caused by a known or unknown pathogen, deliberate and advanced research expertise, planning, and development are crucial for a rapid and strategic response. Our government and industry partners enable the accelerated development of medical countermeasures and global defense. The collaboration between USAMRIID and Mount Sinai will enhance the world’s capabilities for an integrated response to the current and future global pandemics,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn Mount Sinai and President for Academic Affairs at Mount Sinai Health System.

Full release -

[tongosti] 12/5/2021 16:13

Someone the other day branded this down price action as noise. Am sure you all are filing up your boots today. Hang on - where's the excitement? Lol.

[tongosti] 12/5/2021 14:59

Chris - any comment on the share price dear? Lol.

[chris16041] 11/5/2021 07:40

I have so far resisted the temptation to filter Mr Market
I too don't post much and exclusively on shares where I have an interest
I feel I have a duty to novice investors to call out fathead like Mr Market

[davr0s] 10/5/2021 21:59

Lol - suprisingly I'm not a big poster on ADVFN these days - i have a very clear on how I trade/invest these days and opinions don't sway me - I just drop by for the odd bit of sport lol

[sharw] 10/5/2021 20:48

DavROs - please do what most of us here do and filter her/him. If you reply you will just provoke another post and waste the time of the rest of us. My board said there were 7 new posts here so I opened this thread only to find 4 filtered posts and 3 replies from you.

[tongosti] 10/5/2021 14:20

Preaching to the converted. I have given up on predicting a long time ago (learned the hard way). Bending with the market is my game. And that inevitably leads one to assessing probabilities and sharpen tape reading skills. If and when this breaks out properly I will na back on the train like I once was. Until then I'd rather wait. Patiently.

[davr0s] 10/5/2021 14:13

I simply don't predict or try to analyse. I could easily go create a bull or a bear case if I wanted but that doesn't help me - in fact it risks reinforcing my bias. I treat all this stuff as noise - it's still in a strong uptrend and that's all I care about. And is if by magic it's blue again....

[tongosti] 10/5/2021 13:40

I am not trying to rationalise - it's simply a matter of looking at the failure off previous highs in conjunction with the latest director sell. Yes - I agree with you that director transactions do not necessarily hold any predicting value necessarily. I still take them into account and put them in context. As you are trend trading this, am sure you know that only a bo > 80 in good volumes is the sign one should await for (me included). Until then, I personally don't like giving shares the benefit of the doubt. But that's me so good luck with your strategy.

[davr0s] 10/5/2021 13:29

I think you are trying to identify reasons why it is going down short term. My experience is that directors are pretty bad in timing their sells based on looking at what happens on share prices in the past so I pay little attention. I'm trend trading this one - earnings were accelerating last time I looked and it's still only a mild retrace in an uptrend which all rising shares do. So not remotely concerned. But my approach doesn't try and predict so a retrace can develop into a trend break but we are nowhere near this atm